ArticleBMC pharmacology2006
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
Article in BMC pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
217 citing papers in PubMed, 8 syntheses or guidelines pooled it, 418 citations in OpenAlex.
- Enhanced and Prolonged Euphoria during Co-Use of Alcohol and Cocaine: A Narrative and Integrative Review.European addiction research · 2026Pooled it
- Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Efficacité et innocuité du modafinil pour le traitement des troubles liés à l'usage de stimulants de type amphétamine : revue systématique et méta-analyse d'essais randomisés contrôlés par placebo.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Pooled it
- Additive effects of EEG neurofeedback on medications for ADHD: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Effects of neurofeedback versus methylphenidate for the treatment of ADHD: systematic review and meta-analysis of head-to-head trials.Evidence-based mental health · 2019Pooled it
- Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2019Pooled it
- Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.JAMA psychiatry · 2017Pooled it
- Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.Psychiatric genetics · 2015Pooled it
- Serotonergic gene variation in substance use pharmacotherapy: a systematic review.Pharmacogenomics · 2015Pooled it
- Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.The American journal on addictions · 2019Trial
- Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.Psychopharmacology · 2018Trial
- Increased default-mode variability is related to reduced task-performance and is evident in adults with ADHD.NeuroImage. Clinical · 2017Trial
- Amphetamine increases activity but not exploration in humans and mice.Psychopharmacology · 2016Trial
- Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans.Psychoneuroendocrinology · 2014Trial
- Effects of MDMA and Intranasal oxytocin on social and emotional processing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Monoaminergic modulation of behavioural and electrophysiological indices of error processing.Psychopharmacology · 2014Trial
- Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.Genes, brain, and behavior · 2012Trial
- Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.PloS one · 2012Trial
- Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Trial
- Atomoxetine attenuates dextroamphetamine effects in humans.The American journal of drug and alcohol abuse · 2009Trial
- Disulfiram enhances subjective effects of dextroamphetamine in humans.Pharmacology, biochemistry, and behavior · 2008Trial
157 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe plasma membrane neurotransmitter transporters terminate neurotransmissions by the reuptake of the released neurotransmitters. The transporters for the monoamines dopamine, norepinephrine, and serotonin (DAT, NET, and SERT) are targets for several popular psychostimulant drugs of abuse. The potencies of the psychostimulant on the monoamine transporters have been studied by several laboratories. However, there are significant discrepancies in the reported data with differences up to 60-fold. In addition, the drug potencies of the 3 monoamine transporters from mouse have not been compared in the same experiments or along side the human transporters. Further studies and systematic comparisons are needed.
resultsIn this study, we compared the potencies of five psychostimulant drugs to inhibit human and mouse DAT, SERT and NET in the same cellular background. The KI values of cocaine to inhibit the 3 transporters are within a narrow range of 0.2 to 0.7 microM. In comparison, methylphenidate inhibited DAT and NET at around 0.1 microM, while it inhibited SERT at around 100 microM. The order of amphetamine potencies was NET (KI = 0.07-0.1 microM), DAT (KI approximately 0.6 microM), and SERT (KI between 20 to 40 microM). The results for methamphetamine were similar to those for amphetamine. In contrast, another amphetamine derivative, MDMA (3-4 methylenedioxymethamphetamine), exhibited higher potency at SERT than at DAT. The human and mouse transporters were similar in their sensitivities to each of the tested drugs (KI values are within 4-fold).
conclusionThe current and previous studies support the following conclusions: 1) cocaine blocks all 3 monoamine transporters at similar concentrations; 2) methylphenidate inhibits DAT and NET well but a 1000-fold higher concentration of the drug is required to inhibit SERT; 3) Amphetamine and methamphetamine are most potent at NET, while being 5- to 9-fold less potent at DAT, and 200- to 500-fold less potent at SERT; 4) MDMA has moderately higher apparent affinity for SERT and NET than for DAT. The relative potencies of a drug to inhibit DAT, NET and SERT suggest which neurotransmitter systems are disrupted the most by each of these stimulants and thus the likely primary mechanism of drug action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.